Domain > www.trevena.com

Welcome! Right click nodes and scroll the mouse to navigate the graph.

More information on this domain is in AlienVault OTX

DNS Resolutions

Date	IP Address
2020-11-27	35.156.30.200 (ClassC)
2025-02-03	54.151.116.36 (ClassC)
2025-02-11	52.53.123.0 (ClassC)

HTTP/1.1 200 OKDate: Mon, 03 Feb 2025 09:39:56 GMTServer: ApacheX-Frame-Options: SAMEORIGINStrict-Transport-Security: max-age31536000;X-XSS-Protection: 1; modeblockX-Content-Type-Options: nosniffFeatu

!DOCTYPE html>html langen>    head>        meta http-equivx-ua-compatible contentieedge>        meta charsetutf-8>                        link relalternate typeapplication/rss+xml titleTrevena, Inc. - Recent News hrefhttps://www.trevena.com/investors/press-releases/rss />                        title>Trevena, Inc. (TRVN)/title>                link relcanonical hrefhttps://www.trevena.com>meta propertyog:url contenthttps://www.trevena.com>meta propertyog:site_name contentTrevena, Inc.>meta propertyog:title contentTrevena, Inc.>meta propertyog:type contentwebsite>meta propertyog:image contenthttps://d1io3yog0oux5.cloudfront.net/_0299dbeb97a2477627405be72a9d963b/trevena/db/796/6729/social_image_resized.png>meta nametwitter:card contentsummary_large_image>script typeapplication/ld+json>	{@context:http://schema.org,@type:Corporation,name:Trevena, Inc.,address:{@type:PostalAddress,streetAddress:955 Chesterbrook Blvd Suite 110,addressLocality:Chesterbrook, PA,postalCode:19087,addressCountry:},legalName:Trevena, Inc.,description:Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system disorders. The company has four novel and differentiated drug development programs. OLINVYKu00ae is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. The company has three investigational drug candidates, including TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. The company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating diabetic neuropathic pain, epilepsy, and other CNS disorders.,tickerSymbol:: TRVN,url:https://www.trevena.com,logo:https://d1io3yog0oux5.cloudfront.net/_0299dbeb97a2477627405be72a9d963b/trevena/logo.png,image:https://d1io3yog0oux5.cloudfront.net/_0299dbeb97a2477627405be72a9d963b/trevena/db/796/6729/social_imag

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > www.trevena.com

Is this malicious?

DNS Resolutions

Port 443